Zobrazeno 1 - 5
of 5
pro vyhledávání: '"E. R. Allan"'
Autor:
Jonathan Thomas, Dennis S. Charney, Weichun Xu, Joyce A. Cramer, Linda K. Frisman, Joseph Erdos, E. R. Allan, William G. Henderson, Robert A. Rosenheck
Publikováno v:
Archives of General Psychiatry. 56:565-572
Background This study examined the relationship between pretreatment hospital use and the cost-effectiveness of clozapine in the treatment of refractory schizophrenia. Methods Data from a 15-site randomized clinical trial were used to compare clozapi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::683b5f9370b52cfca1d67dc284052895
https://doi.org/10.1001/archpsyc.56.6.565
https://doi.org/10.1001/archpsyc.56.6.565
Publikováno v:
Europe PubMed Central
Background : This study assessed the safety and efficacy of nadolol 120 mg/day compared with placebo, when administered adjunctively to neuroleptic in a group of acutely aggressive schizophrenic patients. Method : Thirty-four male patients enrolled i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1d1aaca5f03ddf21a459528a6f90e92
https://doi.org/10.4088/jcp.v57n1003
https://doi.org/10.4088/jcp.v57n1003
Publikováno v:
Psychopharmacology bulletin. 34(1)
We attempted to develop and validate a computer-driven patient self-rated questionnaire [COSAPSQ] which should provide a reliable, rapid, and inexpensive method to assess symptom severity in patients with psychosis in general and with schizophrenia i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d13aa1a00797a30630dac2960ec44d5c
https://pubmed.ncbi.nlm.nih.gov/9564192
https://pubmed.ncbi.nlm.nih.gov/9564192
Publikováno v:
Psychopharmacology bulletin. 34(1)
Atypical neuroleptics present a unique opportunity to examine confounding by neuroleptic-induced extrapyramidal symptoms (EPS) in the assessment of negative signs of schizophrenia. EPS, such as facial bradykinesia and akinesia, involve some of the sa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::17ee7d99783913a21ceb722eac55e6d7
https://pubmed.ncbi.nlm.nih.gov/9564201
https://pubmed.ncbi.nlm.nih.gov/9564201
Autor:
David A. Smelson, David A. Graeber, E. R. Allan, Wen Liu-Mares, E. Cabrina Campbell, June Corwin, Deborah A. Perlick, Lori L. Davis, Lawrence A. Dunn, Lawrence Herz, Joseph Collins, William Lawson, Stephen F. Bingham, Stanley N. Caroff, Denise R. Evans, Stuart R. Warren, Ede Frecska, John Grabowski, Felicitas Mena, Javaid I. Sheikh, Douglas L. Leslie, Richard Douyon, Kong Kwon, Robert A. Rosenheck, Valerie Smith-Gamble
Publikováno v:
JAMA. 290:2693
ContextAlthough olanzapine has been widely adopted as a treatment of choice for schizophrenia, its long-term effectiveness and costs have not been evaluated in a controlled trial in comparison with a standard antipsychotic drug.ObjectiveTo evaluate t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f74e29f271eb8af8e24a0e9e08e86d1c
https://doi.org/10.1001/jama.290.20.2693
https://doi.org/10.1001/jama.290.20.2693